Table 4.
Top 50 Canonical Pathways
| Ingenuity Canonical Pathways | −log(P Value) | P Value | Ratio | Molecules |
|---|---|---|---|---|
| Pathways regulated in proliferative endometrium (PE) from severe endometriosis vs mild PE | ||||
| Neuregulin signaling | 6.25E00 | .000001 | 0.11 | ITGB1, BAD, PTPN11, HSP90AB1, RRAS, PIK3R1, DCN, HSP90AA1, PDPK1, PTEN, EGFR |
| Prostate cancer signaling | 4.83E00 | .000015 | 0.09 | BAD, TFDP1, PIK3C2A, HSP90AB1, RRAS, PIK3R1, HSP90AA1, PDPK1, PTEN |
| Non-small cell lung cancer signaling | 4.64E00 | .000023 | 0.10 | CDKN2A, BAD, TFDP1, PIK3C2A, RRAS, PIK3R1, PDPK1, EGFR |
| PI3K/AKT signaling | 4.35E00 | .000045 | 0.07 | ITGB1, JAK1, BAD, HSP90AB1, RRAS, PIK3R1, YWHAZ, HSP90AA1, PDPK1, PTEN |
| Chronic myeloid leukemia signaling | 4.27E00 | .000054 | 0.09 | CDKN2A, CTBP1, BAD, TFDP1, PTPN11, PIK3C2A, RRAS, PIK3R1, CBLC |
| Myc-mediated apoptosis signaling | 4.17E00 | .000068 | 0.12 | CDKN2A, BAD, PIK3C2A, RRAS, PIK3R1, YWHAZ, BAX |
| Melanoma signaling | 3.98E00 | .000105 | 0.13 | CDKN2A, BAD, PIK3C2A, RRAS, PIK3R1, PTEN |
| IGF-1 signaling | 3.69E00 | .000204 | 0.08 | BAD, PTPN11, PIK3C2A, RRAS, PIK3R1, YWHAZ, PDPK1, IGFBP5 |
| P70S6K signaling | 3.51E00 | .000309 | 0.07 | GNAI2, JAK1, BAD, PIK3C2A, RRAS, PIK3R1, YWHAZ, PDPK1, EGFR |
| Endometrial cancer signaling | 3.45E00 | .000355 | 0.11 | BAD, PIK3C2A, RRAS, PIK3R1, PDPK1, PTEN |
| Docosahexaenoic acid (DHA) signaling | 3.39E00 | .000407 | 0.11 | BAD, PIK3C2A, PIK3R1, PDPK1, BAX |
| FAK signaling | 3.1E00 | .000794 | 0.07 | ITGB1, PIK3C2A, RRAS, PIK3R1, PDPK1, PTEN, EGFR |
| PTEN signaling | 2.89E00 | .001288 | 0.07 | ITGB1, BAD, RRAS, PIK3R1, PDPK1, PTEN, EGFR |
| FLT3 signaling in hematopoietic progenitor cells | 2.83E00 | .001479 | 0.08 | BAD, PTPN11, PIK3C2A, RRAS, PIK3R1, PDPK1 |
| Glioma signaling | 2.75E00 | .001778 | 0.06 | CDKN2A, TFDP1, PIK3C2A, RRAS, PIK3R1, PTEN, EGFR |
| CNTF signaling | 2.75E00 | .001778 | 0.09 | JAK1, PTPN11, PIK3C2A, RRAS, PIK3R1 |
| Insulin receptor signaling | 2.68E00 | .002089 | 0.06 | JAK1, BAD, PTPN11, PIK3C2A, RRAS, PIK3R1, PDPK1, PTEN |
| Pancreatic adenocarcinoma signaling | 2.6E00 | .002512 | 0.06 | CDKN2A, JAK1, BAD, TFDP1, PIK3C2A, PIK3R1, EGFR |
| IL-2 signaling | 2.56E00 | .002754 | 0.09 | JAK1, PTPN11, PIK3C2A, RRAS, PIK3R1 |
| Molecular mechanisms of cancer | 2.49E00 | .003236 | 0.04 | CDKN2A, JAK1, PIK3C2A, BAD, TFDP1, RRAS, PIK3R1, MAP3K7IP2, GNA11, BAX, APH1A (includes EG:51107), GNAI2, PTPN11, FZD2 |
| FcγRIIB signaling in B lymphocytes | 2.31E00 | .004898 | 0.07 | PIK3C2A, RRAS, PIK3R1, PDPK1 |
| JAK/Stat signaling | 2.3E00 | .005012 | 0.08 | JAK1, PTPN11, PIK3C2A, RRAS, PIK3R1 |
| p53 signaling | 2.29E00 | .005129 | 0.07 | CDKN2A, SCO2 (includes EG:9997), PIK3C2A, PIK3R1, BAX, PTEN |
| Glucocorticoid receptor signaling | 2.28E00 | .005248 | 0.04 | HSPA8, JAK1, PIK3C2A, HSP90AB1, RRAS, GTF2H4, PIK3R1, ANXA1, HSP90AA1, CCL5, UBE2I |
| Angiopoietin signaling | 2.27E00 | .005370 | 0.07 | BAD, PTPN11, PIK3C2A, RRAS, PIK3R1 |
| ERK5 signaling | 2.24E00 | .005754 | 0.07 | BAD, PTPN11, RRAS, YWHAZ, EGFR |
| Neurotrophin/TRK signaling | 2.18E00 | .006607 | 0.06 | PTPN11, PIK3C2A, RRAS, PIK3R1, PDPK1 |
| IL-3 signaling | 2.04E00 | .009120 | 0.07 | JAK1, BAD, PIK3C2A, RRAS, PIK3R1 |
| Agrin interactions at neuromuscular junction | 2.04E00 | .009120 | 0.07 | ITGB1, RRAS, LAMB1, CTTN, EGFR |
| EGF signaling | 2.01E00 | .009772 | 0.08 | JAK1, PIK3C2A, PIK3R1, EGFR |
| Aryl hydrocarbon receptor signaling | 1.89E00 | .012882 | 0.04 | CDKN2A, NFIC, TFDP1, HSP90AB1, HSP90AA1, GSTT2, BAX |
| 14-3-3-mediated signaling | 1.86E00 | .013804 | 0.05 | BAD, PIK3C2A, RRAS, PIK3R1, YWHAZ, BAX |
| Aldosterone signaling in epithelial cells | 1.83E00 | .014791 | 0.05 | HSPA8, PIK3C2A, PIK3R1, HSP90AA1, PDPK1 |
| EIF2 signaling | 1.79E00 | .016218 | 0.05 | PIK3C2A, RRAS, PIK3R1, EIF4G3, PDPK1 |
| Thrombopoietin signaling | 1.77E00 | .016982 | 0.06 | PTPN11, PIK3C2A, RRAS, PIK3R1 |
| Mitotic roles of polo-like kinase | 1.77E00 | .016982 | 0.06 | ANAPC4, HSP90AB1, HSP90AA1, CDC16 |
| IL-9 signaling | 1.73E00 | .018621 | 0.08 | JAK1, PIK3C2A, PIK3R1 |
| Bladder cancer signaling | 1.69E00 | .020417 | 0.05 | CDKN2A, FGFR3, TFDP1, RRAS, EGFR |
| Colorectal cancer metastasis signaling | 1.68E00 | .020893 | 0.04 | JAK1, BAD, PIK3C2A, RRAS, PIK3R1, IFNGR1, BAX, FZD2, EGFR |
| G beta gamma signaling | 1.63E00 | .023442 | 0.04 | GNAI2, RRAS, GNA11, PDPK1, EGFR |
| IL-15 signaling | 1.6E00 | .025119 | 0.06 | JAK1, PIK3C2A, RRAS, PIK3R1 |
| Hypoxia signaling in the Cardiovascular system | 1.58E00 | .026303 | 0.06 | HSP90AB1, HSP90AA1, PTEN, UBE2I |
| GM-CSF signaling | 1.58E00 | .026303 | 0.06 | PTPN11, PIK3C2A, RRAS, PIK3R1 |
| IL-4 signaling | 1.53E00 | .029512 | 0.06 | JAK1, PIK3C2A, RRAS, PIK3R1 |
| Macropinocytosis signaling | 1.53E00 | .029512 | 0.06 | ITGB1, PIK3C2A, RRAS, PIK3R1 |
| Erythropoietin signaling | 1.51E00 | .030903 | 0.05 | PIK3C2A, RRAS, PIK3R1, PDPK1 |
| Fc Epsilon RI signaling | 1.51E00 | .030903 | 0.05 | PTPN11, PIK3C2A, RRAS, PIK3R1, PDPK1 |
| Huntington disease signaling | 1.48E00 | .033113 | 0.03 | HSPA8, PIK3C2A, PIK3R1, GNA11, STX16, PDPK1, BAX, EGFR |
| HGF signaling | 1.47E00 | .033884 | 0.05 | CDKN2A, PTPN11, PIK3C2A, RRAS, PIK3R1 |
| iCOS-iCOSL signaling in T Helper Cells | 1.46E00 | .034674 | 0.04 | BAD, PIK3C2A, PIK3R1, PDPK1, PTEN |
| Pathways regulated in early secretory endometrium (ESE) from severe endometriosis vs mild ESE | ||||
| Complement system | 3.54E00 | .00029 | 0.19 | CFD, SERPING1, C1S, CD55, C1QA, CD46, C1QB |
| Hepatic fibrosis/hepatic stellate cell activation | 2.92E00 | .00120 | 0.10 | VCAM1, FN1, PDGFA, IFNGR1, IGFBP5, BAX, CCL5, PGF, MYL9 (includes EG:10398), IGF1, TIMP1, IGFBP3, EGFR |
| IL-8 signaling | 2.72E00 | .00191 | 0.08 | NAPEPLD, VCAM1, PIK3C2A, RRAS, PIK3R1, BAX, IRAK1, PGF, EIF4EBP1, ROCK2, HMOX1, CCND2, RHOD, RHOF, EGFR |
| Clathrin-mediated endocytosis signaling | 2.71E00 | .00195 | 0.08 | ACTR2, PIK3C2A, PDGFA, PIK3R1, ITGB8, PGF, HSPA8, SNX9 (includes EG:51429), IGF1, FGF18, RAB5C, DAB2, CTTN, ITGB5 |
| Docosahexaenoic acid (DHA) signaling | 2.67E00 | .00214 | 0.13 | BAD, FOXO1, PIK3C2A, PIK3R1, BIK, BAX |
| IGF-1 signaling | 2.65E00 | .00224 | 0.10 | IGFBP6, IGF1, BAD, FOXO1, PIK3C2A, RRAS, PIK3R1, IGFBP3, IGFBP5, SFN |
| Prostate cancer signaling | 2.41E00 | .00389 | 0.09 | BAD, TFDP1, FOXO1, PIK3C2A, HSP90AB1, RRAS, SRD5A1, PIK3R1, CREB3L4 |
| Myc-mediated apoptosis signaling | 2.23E00 | .00589 | 0.12 | IGF1, BAD, PIK3C2A, RRAS, PIK3R1, BAX, SFN |
| NRF2-mediated oxidative stress response | 2.1E00 | .00794 | 0.08 | AKR7A2, MGST1, PIK3C2A, RRAS, PIK3R1, MAF, CLPP, MAFF, HMOX1, DNAJC4, GSTT2, GSTO2, FKBP5, PTPLAD1 |
| Ubiquinone biosynthesis | 2.07E00 | .00851 | 0.06 | NDUFB11, NDUFS8, NDUFS7, MGMT, NDUFB7, NDUFA3, ALDH6A1 |
| IL-4 signaling | 1.92E00 | .01202 | 0.10 | HLA-DQB1, SOCS1, HLA-DMA, JAK1, PIK3C2A, RRAS, PIK3R1 |
| VEGF signaling | 1.81E00 | .01549 | 0.08 | ROCK2, BAD, FOXO1, PIK3C2A, RRAS, PIK3R1, SFN, PGF |
| Pancreatic adenocarcinoma signaling | 1.77E00 | .01698 | 0.08 | HMOX1, NAPEPLD, JAK1, BAD, TFDP1, PIK3C2A, PIK3R1, PGF, EGFR |
| Virus entry via endocytic pathways | 1.75E00 | .01778 | 0.08 | PIK3C2A, RRAS, PIK3R1, CD55, CAV1, ITGB8, ITGB5, FOLR1 |
| Caveolar-mediated endocytosis signaling | 1.72E00 | .01905 | 0.09 | CD55, RAB5C, CAV1, COPE, ITGB8, ITGB5, EGFR |
| Axonal guidance signaling | 1.65E00 | .02239 | 0.06 | ACTR2, FZD10, PIK3C2A, UNC5A, RRAS, PDGFA, PIK3R1, GNA11, EFNA4, PGF, MYL9 (includes EG:10398), ROCK2, FZD8, IGF1, GLIS2, RHOD, NTRK3, WNT4, BMP7, EFNB3, RTN4R, FZD2, GLIS1 |
| Role of NANOG in mammalian embryonic stem cell pluripotency | 1.62E00 | .02399 | 0.09 | FZD8, FZD10, JAK1, PIK3C2A, RRAS, PIK3R1, WNT4, BMP7, TCF7L1, FZD2 |
| Fructose and mannose metabolism | 1.56E00 | .02754 | 0.03 | AKR7A2, GMDS, GALK1, FBP1, ALDOA |
| Colorectal cancer metastasis signaling | 1.55E00 | .02818 | 0.06 | FZD10, MMP7, JAK1, PIK3C2A, BAD, RRAS, PIK3R1, IFNGR1, BAX, PGF, FZD8, RHOD, WNT4, RHOF, FZD2, EGFR |
| Interferon signaling | 1.55E00 | .02818 | 0.13 | SOCS1, JAK1, IFITM1, IFNGR1 |
| Glucocorticoid receptor signaling | 1.52E00 | .03020 | 0.06 | VCAM1, JAK1, PIK3C2A, RRAS, PIK3R1, CCL5, SLPI, HSPA8, HSP90AB1, DUSP1, GTF2H4, CDKN1C, FKBP5, POLR2I, UBE2I, ADRB2 |
| VDR/RXR activation | 1.52E00 | .03020 | 0.09 | IGFBP6, FOXO1, PDGFA, IGFBP3, IGFBP5, HES1, CCL5 |
| ILK signaling | 1.51E00 | .03090 | 0.06 | MYL9 (includes EG:10398), PARVB, FN1, PIK3C2A, RHOD, PIK3R1, CREB3L4, ITGB8, RHOF, PPP1R14B, ITGB5, PGF |
| Basal cell carcinoma signaling | 1.47E00 | .03388 | 0.10 | FZD8, FZD10, GLIS2, WNT4, BMP7, FZD2, GLIS1 |
| PI3K/AKT signaling | 1.46E00 | .03467 | 0.07 | JAK1, BAD, FOXO1, HSP90AB1, RRAS, PIK3R1, SFN, EIF4EBP1, THEM4 |
| Human embryonic stem cell pluripotency | 1.44E00 | .03631 | 0.07 | FZD8, FZD10, PIK3C2A, PDGFA, NTRK3, PIK3R1, SMAD6, WNT4, BMP7, FZD2 |
| Wnt/β-catenin signaling | 1.44E00 | .03631 | 0.07 | SOX4, FZD8, SFRP4, FZD10, MMP7, FRZB, CDH3, WNT4, TCF7L1, PIN1, DKK1, FZD2 |
| Macropinocytosis signaling | 1.42E00 | .03802 | 0.08 | PIK3C2A, RRAS, PDGFA, PIK3R1, ITGB8, ITGB5 |
| Non-small cell lung cancer signaling | 1.39E00 | .04074 | 0.08 | BAD, TFDP1, PIK3C2A, RRAS, PIK3R1, EGFR |
| Riboflavin metabolism | 1.39E00 | .04074 | 0.05 | ACP5, ENPP3, ENPP1 |
| FLT3 signaling in hematopoietic progenitor cells | 1.31E00 | .04898 | 0.08 | BAD, PIK3C2A, RRAS, PIK3R1, CREB3L4, EIF4EBP1 |
| Glutathione metabolism | 1.29E00 | .05129 | 0.05 | GPX3, MGST1, GPX1, GSTT2, GSTO2 |
| Selenoamino acid metabolism | 1.28E00 | .05248 | 0.04 | MGMT, PAPSS1 (includes EG:9061), MAT2A |
| p53 signaling | 1.27E00 | .05370 | 0.08 | SCO2 (includes EG:9997), CCND2, PIK3C2A, PIK3R1, RPRM, BAX, SFN |
| IL-2 signaling | 1.26E00 | .05495 | 0.09 | SOCS1, JAK1, PIK3C2A, RRAS, PIK3R1 |
| IL-3 signaling | 1.26E00 | .05495 | 0.08 | JAK1, BAD, FOXO1, PIK3C2A, RRAS, PIK3R1 |
| Amyotrophic lateral sclerosis signaling | 1.25E00 | .05623 | 0.06 | IGF1, PIK3C2A, PIK3R1, RAB5C, GPX1, BAX, PGF |
| 14-3-3-mediated signaling | 1.24E00 | .05754 | 0.07 | BAD, FOXO1, PIK3C2A, RRAS, PIK3R1, BAX, SFN, PLCL1 |
| PDGF signaling | 1.23E00 | .05888 | 0.08 | JAK1, PIK3C2A, RRAS, PDGFA, PIK3R1, CAV1 |
| Acute phase response signaling | 1.22E00 | .06026 | 0.06 | HMOX1, SOCS1, SERPING1, FN1, RBP7, RRAS, C1S, PIK3R1, SERPINA3, SERPINA1, IRAK1 |
| Integrin signaling | 1.21E00 | .06166 | 0.06 | ACTR2, PARVB, PIK3C2A, RHOD, RRAS, PIK3R1, CAV1, ITGB8, RHOF, TSPAN4, ITGB5, RAP2A |
| Nitric oxide signaling in the cardiovascular system | 1.21E00 | .06166 | 0.07 | PIK3C2A, HSP90AB1, PIK3R1, CAV1, SLC7A1, PGF |
| Molecular mechanisms of cancer | 1.21E00 | .06166 | 0.05 | FZD10, JAK1, PIK3C2A, BAD, TFDP1, RRAS, PIK3R1, GNA11, SMAD6, BAX, APH1A (includes EG:51107), FZD8, CCND2, FOXO1, RHOD, IHH, BMP7, RHOF, FZD2, RAP2A |
| HMGB1 signaling | 1.19E00 | .06457 | 0.07 | VCAM1, PIK3C2A, RHOD, RRAS, PIK3R1, IFNGR1, RHOF |
| Nicotinate and nicotinamide metabolism | 1.17E00 | .06761 | 0.05 | ENPP3, PRKX, ENPP1, QPRT, NAMPT, HIPK1, IRAK1 |
| Leukocyte extravasation signaling | 1.14E00 | .07244 | 0.06 | ROCK2, CLDN10, MMP7, VCAM1, PIK3C2A, ICAM3, TIMP1, PIK3R1, RDX, MLLT4, CTTN |
| Glioma signaling | 1.11E00 | .07762 | 0.06 | IGF1, TFDP1, PIK3C2A, RRAS, PDGFA, PIK3R1, EGFR |
| Methionine metabolism | 1.1E00 | .07943 | 0.04 | DNMT3A, IL4I1, MAT2A |
| mTOR signaling | 1.1E00 | .07943 | 0.06 | HMOX1, NAPEPLD, PIK3C2A, RHOD, RRAS, PIK3R1, RHOF, PGF, EIF4EBP1 |
| Melanoma signaling | 1.1E00 | .07943 | 0.09 | BAD, PIK3C2A, RRAS, PIK3R1 |
| Pathways regulated in mid-secretory endometrium (MSE) from severe endometriosis vs mild MSE | ||||
| Neuregulin signaling | 3.13E00 | .00074 | 0.14 | ITGB1, BAD, PIK3R1, DCN, PDPK1, PTEN, ERBB2IP (includes EG:55914), PRKCI, HSP90AB1, PTPN11, CDK5, HSP90AA1, PSEN1, EGFR |
| Acute phase response signaling | 2.63E00 | .00234 | 0.11 | IL6ST, SOCS1, MAP2K7, C1S, PIK3R1, PDPK1, CP, SERPINA3, MAP3K5 (includes EG:4217), IL1R1, TCF3, IRAK1, HMOX1, SOD2, RIPK1, PTPN11, C4BPA, MAP3K7, CRABP2, SERPINA1 |
| Docosahexaenoic acid (DHA) SIGNALING | 2.37E00 | .00427 | 0.16 | BAD, FOXO1, PIK3C2A, PIK3R1, BIK, PDPK1, BAX |
| Wnt/β-catenin signaling | 2.34E00 | .00457 | 0.12 | SOX4, SOX7, FZD10, FRAT1, TCF7L1, TCF3, SOX17, CSNK1E, FZD8, TGFB1, MAP3K7, DKK3, CD44, PIN1, SOX18, SFRP1, DKK1, FZD2, FZD7 |
| Germ cell-sertoli cell junction signaling | 2.14E00 | .00724 | 0.11 | EPN3, ITGB1, MAP2K7, PIK3C2A, CDC42, TJP1, PIK3R1, TUBG1, TUBB2A, PDPK1, MAP3K5 (includes EG:4217), IQGAP1, GSN, RHOQ, TGFB1, MAP3K7, PPAP2B, ACTN1 |
| Clathrin-mediated endocytosis signaling | 2.11E00 | .00776 | 0.10 | ITGB1, ACTR2, PIK3C2A, RAB5A, CDC42, PDGFA, PIK3R1, CLTB, HSPA8, MET, ARRB1, FGF18, RAB5C, DAB2, TFRC, CTTN, ITGB5 |
| Prostate cancer signaling | 2.09E00 | .00813 | 0.12 | BAD, TFDP1, FOXO1, PIK3C2A, HSP90AB1, SRD5A1, PIK3R1, HSP90AA1, PDPK1, CREB3L4, PTEN |
| Mitochondrial dysfunction | 1.94E00 | .01148 | 0.09 | NDUFS7, XDH, NDUFA13, APH1A (includes EG:51107), MAOB, NDUFB11, SOD2, NDUFS8, TXN2, NDUFB7, NDUFA3, CYC1, UQCRC1, PSEN1, MAOA |
| Virus entry via endocytic pathways | 1.89E00 | .01288 | 0.12 | ITGB1, PRKCI, CDC42, PIK3C2A, PIK3R1, CLTB, CD55, CAV1, TFRC, ITGB5, FOLR1 |
| Macropinocytosis signaling | 1.86E00 | .01380 | 0.13 | ITGB1, MET, PRKCI, RAB5A, CDC42, PIK3C2A, PDGFA, PIK3R1, ITGB5 |
| Leukocyte extravasation signaling | 1.83E00 | .01479 | 0.09 | ITGB1, PIK3C2A, CDC42, PIK3R1, RDX, THY1, ROCK2, GNAI2, CLDN23, PRKCI, PTPN11, ICAM3, EZR, CD44, MMP11, CTTN, ACTN1, TIMP2 |
| VDR/RXR activation | 1.78E00 | .01660 | 0.13 | IGFBP6, SPP1, PRKCI, FOXO1, PDGFA, IGFBP5, NCOR2, HES1, CCL5, KLF4 |
| Notch signaling | 1.77E00 | .01698 | 0.16 | RFNG, NOTCH2, NOTCH3, HEY2, HES1, APH1A (includes EG:51107), PSEN1 |
| NRF2-mediated oxidative stress response | 1.5E00 | .03162 | 0.09 | AKR7A2, MAP2K7, PIK3C2A, PIK3R1, SLC35A2, DNAJC13, DNAJC3, MAP3K5 (includes EG:4217), DNAJA1, CLPP, MAFF, MAFG, HMOX1, PRKCI, SOD2, DNAJC4, MAP3K7 |
| Huntington disease signaling | 1.43E00 | .03715 | 0.08 | MAP2K7, CAPN6, PIK3C2A, PIK3R1, GNA11, HSPA9, PDPK1, CREB3L4, BAX, GNG7, HDAC5, HSPA8, PRKCI, GNG11, CDK5, STX16, NCOR2, POLR2I, EGFR |
| Hepatic fibrosis/hepatic stellate cell activation | 1.42E00 | .03802 | 0.10 | PDGFA, FGFR1, FGFR2, IGFBP5, IL1R1, BAX, CCL5, MET, COL1A2, TGFB1, COL3A1, TIMP2, EGFR |
| Insulin receptor signaling | 1.42E00 | .03802 | 0.09 | JAK1, BAD, PIK3C2A, PIK3R1, PDPK1, VAMP2, PTEN, EIF4EBP1, PRKCI, RHOQ, FOXO1, PTPN11, PPP1R12A |
| IGF-1 signaling | 1.42E00 | .03802 | 0.10 | IGFBP6, PRKCI, BAD, FOXO1, PTPN11, PIK3C2A, PIK3R1, YWHAZ, PDPK1, IGFBP5 |
| Neurotrophin/TRK signaling | 1.39E00 | .04074 | 0.10 | MAP2K7, CDC42, PTPN11, PIK3C2A, PIK3R1, PDPK1, CREB3L4, MAP3K5 (includes EG:4217) |
| G beta gamma signaling | 1.39E00 | .04074 | 0.09 | GNAI2, GNAS, GNG11, PRKCI, CDC42, GNA11, CAV1, PDPK1, GNG7, EGFR |
| PI3K/AKT signaling | 1.38E00 | .04169 | 0.09 | ITGB1, JAK1, BAD, FOXO1, HSP90AB1, PIK3R1, YWHAZ, HSP90AA1, PDPK1, MAP3K5 (includes EG:4217), PTEN, EIF4EBP1 |
| Semaphorin signaling in neurons | 1.38E00 | .04169 | 0.13 | ROCK2, ITGB1, MET, RHOQ, CDK5, DPYSL4, NRP1 |
| Mitotic roles of polo-like kinase | 1.38E00 | .04169 | 0.11 | ANAPC4, HSP90AB1, TGFB1, CDC7, HSP90AA1, CDC16, STAG2 |
| Histidine metabolism | 1.37E00 | .04266 | 0.05 | PRPS2, ALDH3B2 (includes EG:222), MAOB, MGMT, ABP1, MAOA |
| SAPK/JNK signaling | 1.36E00 | .04365 | 0.10 | MAP2K7, GNG11, RIPK1, TRD@, CDC42, PIK3C2A, MAP3K7, PIK3R1, MAP3K5 (includes EG:4217), GNG7 |
| Type I diabetes mellitus signaling | 1.34E00 | .04571 | 0.10 | SOCS1, HLA-DMA, MAP2K7, JAK1, RIPK1, TRD@, MAP3K7, IL1R1, MAP3K5 (includes EG:4217), HSPD1, IRAK1 |
| FGF signaling | 1.3E00 | .05012 | 0.10 | MET, PTPN11, PIK3C2A, FGF18, PIK3R1, FGFR1, FGFR2, CREB3L4, MAP3K5 (includes EG:4217) |
| Chronic myeloid leukemia signaling | 1.25E00 | .05623 | 0.10 | CTBP1, RBL2, BAD, TFDP1, PTPN11, PIK3C2A, TGFB1, PIK3R1, CBLC, HDAC5 |
| RAR activation | 1.25E00 | .05623 | 0.08 | CYP26A1, PIK3R1, NR2F2, PDPK1, MAP3K5 (includes EG:4217), PTEN, PRKCI, DUSP1, GTF2H4, TGFB1, CRABP2, RDH5, NCOR2, CARM1, SCAND1 |
| Phenylalanine metabolism | 1.25E00 | .05623 | 0.05 | ALDH3B2 (includes EG:222), MAOB, ABP1, MAOA, PRDX2 |
| 14-3-3-mediated signaling | 1.24E00 | .05754 | 0.10 | PRKCI, BAD, FOXO1, PIK3C2A, PIK3R1, TUBB2A, TUBG1, YAP1, YWHAZ, BAX, MAP3K5 (includes EG:4217) |
| Caveolar-mediated endocytosis signaling | 1.23E00 | .05888 | 0.10 | ITGB1, RAB5A, CD55, RAB5C, CAV1, COPE, ITGB5, EGFR |
| Ubiquinone biosynthesis | 1.17E00 | .06761 | 0.06 | NDUFB11, NDUFS8, NDUFS7, MGMT, NDUFB7, NDUFA3, NDUFA13 |
| RAN signaling | 1.17E00 | .06761 | 0.13 | KPNB1, RANBP2, RAN |
| ILK signaling | 1.11E00 | .07762 | 0.08 | MUC1, ITGB1, PIK3C2A, CDC42, PIK3R1, FERMT2, PDPK1, CREB3L4, PTEN, PARVB, RHOQ, PPAP2B, CHD1 (includes EG:1105), ACTN1, ITGB5 |
| Human embryonic stem cell pluripotency | 1.07E00 | .08511 | 0.08 | FZD8, GNAS, FZD10, PIK3C2A, PDGFA, TGFB1, PIK3R1, FGFR1, FGFR2, PDPK1, FZD2, FZD7 |
| B Cell receptor signaling | 1.06E00 | .08710 | 0.08 | MAP2K7, BAD, CDC42, PIK3C2A, PIK3R1, CREB3L4, MAP3K5 (includes EG:4217), PTEN, PTPRC, PTPN11, CARD10, MAP3K7, PAG1 |
| Ephrin receptor signaling | 1.04E00 | .09120 | 0.08 | ITGB1, ACTR2, CDC42, PDGFA, GNA11, CREB3L4, GNG7, EFNA4, ROCK2, GNAI2, EPHB6, GNAS, GNG11, PTPN11, EFNB3 |
| Pentose phosphate pathway | 9.86E-01 | .10328 | 0.04 | PRPS2, PGLS, FBP1, ALDOA |
| Melanoma signaling | 9.75E-01 | .10593 | 0.11 | BAD, PIK3C2A, PIK3R1, CHD1 (includes EG:1105), PTEN |
| CCR5 signaling in macrophages | 9.7E-01 | .10715 | 0.08 | GNAI2, GNAS, GNG11, PRKCI, TRD@, CCL5, GNG7 |
| FLT3 signaling in hematopoietic progenitor cells | 9.45E-01 | .11350 | 0.10 | BAD, PTPN11, PIK3C2A, PIK3R1, PDPK1, CREB3L4, EIF4EBP1 |
| Oxidative phosphorylation | 9.28E-01 | .11803 | 0.08 | ATP6V0E2, ATP6V0B, ATP5D, NDUFS7, TCIRG1, ATP6V1A, NDUFA13, NDUFB11, NDUFS8, NDUFB7, NDUFA3, CYC1, UQCRC1 |
| IL-8 signaling | 9.27E-01 | .11830 | 0.07 | PIK3C2A, PIK3R1, BAX, GNG7, EIF4EBP1, IRAK1, ROCK2, GNAI2, HMOX1, GNAS, GNG11, PRKCI, RHOQ, EGFR |
| Fructose and mannose metabolism | 9.1E-01 | .12303 | 0.04 | AKR7A2, TSTA3, GMPPA, FBP1, ALDOA, FUK |
| Cdc42 signaling | 9E-01 | .12589 | 0.08 | ITGB1, ANAPC4, ACTR2, PRKCI, TRD@, CDC42, CDC42EP5, PPP1R12A, CDC16, IQGAP1 |
| Arginine and proline metabolism | 8.96E-01 | .12706 | 0.04 | CKB, MAOB, VNN1, GAMT, LOXL1, ABP1, MAOA |
| HGF signaling | 8.69E-01 | .13521 | 0.09 | MET, MAP2K7, PRKCI, CDC42, PTPN11, PIK3C2A, MAP3K7, PIK3R1, MAP3K5 (includes EG:4217) |
| EGF signaling | 8.5E-01 | .14125 | 0.10 | MAP2K7, JAK1, PIK3C2A, PIK3R1, EGFR |
| Nitric oxide signaling in the cardiovascular system | 8.49E-01 | .14158 | 0.08 | PIK3C2A, HSP90AB1, PIK3R1, CAV1, HSP90AA1, SLC7A1, CACNA1A |